产品
编 号：F754162
分子式：C21H25N5S
分子量：379.52
分子式：C21H25N5S
分子量：379.52
产品类型
规格
价格
是否有货
结构图
CAS No: 2636771-29-2
产品详情
生物活性：
PKC-IN-4 (compound 7l) is a potent and orally active aPKC inhibitor with an IC50 of 0.52 μM. PKC-IN-4 inhibits TNF-α induced NF-κB activity in vitro. PKC-IN-4 blocks VEGF- and TNFα-induced permeability across the retinal vasculature.
体内研究：
PKC-IN-4 (10 mg/kg for i.v.; 20 mg/kg for p.o.) shows orally active with oral bioavailability of 81.7%.Animal Model:Animal Model: CD-1 mice
Dosage:10, 20 mg/kg
Administration:10 mg/kg for i.v.; 20 mg/kg for p.o.
Result:Showed good PK parameters with oral bioavailability of 81.7%.
体外研究：
PKC-IN-4 (compound 7l) shows VEGF - induced endothelial permeability with an EC50 of 0.071 μM.
PKC-IN-4 (compound 7l) is a potent and orally active aPKC inhibitor with an IC50 of 0.52 μM. PKC-IN-4 inhibits TNF-α induced NF-κB activity in vitro. PKC-IN-4 blocks VEGF- and TNFα-induced permeability across the retinal vasculature.
体内研究：
PKC-IN-4 (10 mg/kg for i.v.; 20 mg/kg for p.o.) shows orally active with oral bioavailability of 81.7%.Animal Model:Animal Model: CD-1 mice
Dosage:10, 20 mg/kg
Administration:10 mg/kg for i.v.; 20 mg/kg for p.o.
Result:Showed good PK parameters with oral bioavailability of 81.7%.
体外研究：
PKC-IN-4 (compound 7l) shows VEGF - induced endothelial permeability with an EC50 of 0.071 μM.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备